Overview

The Contribution of Incretin Hormones to the Amelioration of Glucose Metabolism After Roux-en-Y Gastric Bypass

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
0
Participant gender:
All
Summary
The study is being undertaken to understand how a gastric bypass can affect a subject's diabetes even prior to their losing significant amounts of weight. The hypothesis of this study is that increased glucagon-like peptide-1 (GLP-1) secretion explains the amelioration in insulin secretion after Roux-en-Y Gastric Bypass (RYGB) surgery.
Phase:
Early Phase 1
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Adrian Vella
Collaborators:
National Center for Research Resources (NCRR)
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Treatments:
Gastric Inhibitory Polypeptide
Hormones
Incretins
Criteria
Inclusion Criteria:

- Subjects with type 2 diabetes mellitus or impaired fasting glucose concentration of >
110 mg/dL

- Subjects registered to receive a Roux-en-Y Gastric Bypass (RYGB).

Exclusion Criteria:

- Subjects taking thiazolidinediones

- Subjects with active systemic illness

- Subjects with active microvascular or macrovascular complications of their diabetes

- For female subject: positive pregnancy test at the time of enrollment in study